Navigation Links
Horse antibodies against the bird flu virus H5N1 are effective as treatment in mice

Antibodies against the bird flu virus H5N1, derived from horses, prevent mice infected with H5N1 from dying from the virus.

A study published today in the open access journal Respiratory Research (http://respiratory-research.com) reveals that a dose of 100 µg of horse anti-serum effectively protects infected mice. These results suggest that anti-H5N1 antibodies developed in horses could potentially be used to prevent death from H5N1 influenza, or as early treatment for the disease, in humans.

Jiahai Lu from Sun Yat-Sen University in Guangzhou, China and colleagues from other institutions in China infected dog kidney cells in vitro with a lethal dose of H5N1 and simultaneously exposed the cells to horse antibodies against H5N1. Lu et al.'s results show that horse antibodies to H5N1 protected cells against H5N1 in vitro ?the cells simultaneously infected with H5N1 and exposed to horse antibodies did not die.

Lu et al. then injected horse antibodies into 40 mice that had been infected with a lethal dose of H5N1 24 hours earlier. The authors also injected horse serum without H5N1 antibodies into a group of mice that acted as controls.

The authors found that 50µg of antibody protected 70% of the mice against death by H5N1 and 100 µg of antibody protected 100% of the mice. The mice in the control group died nine hours after receiving the normal horse serum.


'"/>

Source:BioMed Central


Page: 1

Related biology news :

1. Horseshoe crab decline threatens shorebird species
2. Trojan Horse agent halts bone metastasis in mice
3. Horse genome assembled
4. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
5. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
6. Mice studies illustrate potential of chimp/human antibodies to protect against smallpox
7. GlycoFi announces the first production of antibodies with human glycosylation in yeast
8. Data published in PNAS show antibodies can be made 10 times more toxic to cancer cells
9. Report calls for improved monoclonal antibodies against solid tumors
10. Cheaper, better disease treatments expected from faster approach to developing antibodies
11. Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/8/2016)... , January 8, 2016 NXTD ... and WorldVentures ® , a privately held leading direct ... Inc. 5000 fastest-growing company announced that on ... of $2 million in Nxt-ID to develop a proprietary ... Nxt-ID,s Wocket ® , a unique smart wallet that ...
(Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
(Date:1/6/2016)... , Jan. 6, 2016  Varam Capital, a ... their trusted partner to deliver advanced authentication solutions to ... services to the poor. A loan of a few ... lives, giving them the ability to purchase livestock or ... make clothing, or stock for a local store. ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at FireflySci, ... What sets them apart from other cuvette manufacturers is their supercharged customer service ... On top of this steady flow of inside information, they have recently revamped ...
(Date:2/3/2016)... -- Ascendis Pharma A/S (Nasdaq: ASND ), a ... technology to address significant unmet medical needs, today announced ... Partners Global Healthcare Conference Location: , Waldorf Astoria, ... Time:  , 11:55am EST www.ascendispharma.com . ... audio webcast of this event will be posted to ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
(Date:2/3/2016)... ALTO, Calif. , Feb. 3, 2016  Today, ... sale of AlphaImpactRx , a leading provider of ... health companies to IMS Health , a global ... AlphaImpactRx,s complementary offerings, capabilities and technologies will be integrated ... company,s growing global primary market research capabilities. ...
Breaking Biology Technology: